Nothing Special   »   [go: up one dir, main page]

ES2191784T3 - Vacunas de tumores de citocinas paracrinas alogenicas. - Google Patents

Vacunas de tumores de citocinas paracrinas alogenicas.

Info

Publication number
ES2191784T3
ES2191784T3 ES96945109T ES96945109T ES2191784T3 ES 2191784 T3 ES2191784 T3 ES 2191784T3 ES 96945109 T ES96945109 T ES 96945109T ES 96945109 T ES96945109 T ES 96945109T ES 2191784 T3 ES2191784 T3 ES 2191784T3
Authority
ES
Spain
Prior art keywords
cell line
tumor cell
tumor
line
citocines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96945109T
Other languages
English (en)
Inventor
Elizabeth M Jaffee
Drew M Pardoll
Hyam I Levitsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
School of Medicine of Johns Hopkins University
Original Assignee
Johns Hopkins University
School of Medicine of Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24318022&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2191784(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Johns Hopkins University, School of Medicine of Johns Hopkins University filed Critical Johns Hopkins University
Application granted granted Critical
Publication of ES2191784T3 publication Critical patent/ES2191784T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001139—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCION DESCRIBE UN PROCEDIMIENTO PARA TRATAR EL CANCER QUE INCLUYE (A) OBTENER UNA LINEA CELULAR TUMORAL, (B) MODIFICAR LA LINEA CELULAR TUMORAL PARA QUE SEA CAPAZ DE PRODUCIR UN NIVEL AUMENTADO DE UNA CITOCINA EN RELACION A LA LINEA CELULAR TUMORAL NO MODIFICADA, Y (C) ADMINISTRAR LA LINEA CELULAR TUMORAL A UN HUESPED MAMIFERO QUE PRESENTA AL MENOS UN TUMOR QUE ES EL MISMO TIPO DE TUMOR DEL CUAL SE HA OBTENIDO LA LINEA CELULAR TUMORAL, SIENDO LA LINEA CELULAR TUMORAL ALOGENICA Y NO PRESENTANDO EMPAREJAMIENTO MHC CON EL HUESPED. LA PRESENTE INVENCION TAMBIEN DESCRIBE UNA LINEA CELULAR TUMORAL PANCREATICA, UN PROCEDIMIENTO Y UN MEDIO PARA OBTENER DICHA LINEA CELULAR TUMORAL, Y UNA COMPOSICION FORMADA POR CELULAS DE UN LINEA CELULAR TUMORAL PANCREATICA PURIFICADA.
ES96945109T 1995-12-28 1996-12-26 Vacunas de tumores de citocinas paracrinas alogenicas. Expired - Lifetime ES2191784T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57970895A 1995-12-28 1995-12-28

Publications (1)

Publication Number Publication Date
ES2191784T3 true ES2191784T3 (es) 2003-09-16

Family

ID=24318022

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96945109T Expired - Lifetime ES2191784T3 (es) 1995-12-28 1996-12-26 Vacunas de tumores de citocinas paracrinas alogenicas.

Country Status (7)

Country Link
EP (1) EP0869803B1 (es)
JP (1) JP2000502711A (es)
AT (1) ATE237338T1 (es)
AU (1) AU1355697A (es)
DE (1) DE69627527T2 (es)
ES (1) ES2191784T3 (es)
WO (1) WO1997024132A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9620350D0 (en) 1996-09-30 1996-11-13 Maudsley David J Cancer vaccine
EP0893507A1 (en) * 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
DE19832840C1 (de) * 1998-07-21 2000-06-08 Kerkmann Tucek Aida Mittel zur Immuntherapie von Tumorerkrankungen
GB9827103D0 (en) 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
AU4935700A (en) * 1999-05-21 2000-12-12 Onyvax Limited New vaccine formulations-3
ATE259655T1 (de) * 1999-05-21 2004-03-15 Onyvax Ltd Aus ganzen zellen bestehender krebs-impfstoff, enthaltend ko-kultivierte maligne und nicht- maligne zellen
GB9911823D0 (en) * 1999-05-21 1999-07-21 Onyvax Ltd New vaccine formulations
WO2001075073A2 (en) 2000-04-01 2001-10-11 Onyvax Limited Prostate cell lines and their use
WO2003039592A2 (de) * 2001-11-09 2003-05-15 Medigene Aktiengesellschaft Zelluläre impfstoffe mit adjuvanzien
US9200036B2 (en) 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
CA2492160A1 (en) 2002-07-12 2004-01-22 The Johns Hopkins University Mesothelin vaccines and model systems
US20090110702A1 (en) 2002-07-12 2009-04-30 The Johns Hopkins University Mesothelin Vaccines and Model Systems and Control of Tumors
US7176022B2 (en) 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products
US20050019336A1 (en) 2003-07-23 2005-01-27 Dalgleish Angus George Human prostate cell lines in cancer treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2002025A1 (en) * 1988-11-02 1990-05-02 Geary W. Collins Continuous mammalian cell lines having monocyte-macrophage characteristics and their establishment in vitro
DK0551401T3 (da) * 1990-09-14 1996-01-22 Univ Texas Fremgangsmåde og præparater til genterapi og potensering af antitumor-immunitet
WO1994004196A1 (en) * 1992-08-14 1994-03-03 Imperial Cancer Research Technology Limited Tumour therapy

Also Published As

Publication number Publication date
WO1997024132A1 (en) 1997-07-10
JP2000502711A (ja) 2000-03-07
DE69627527D1 (en) 2003-05-22
AU1355697A (en) 1997-07-28
DE69627527T2 (de) 2004-03-04
EP0869803A1 (en) 1998-10-14
EP0869803B1 (en) 2003-04-16
ATE237338T1 (de) 2003-05-15

Similar Documents

Publication Publication Date Title
ES2191784T3 (es) Vacunas de tumores de citocinas paracrinas alogenicas.
DK1468014T3 (da) Sammensætninger og fremgangsmåder til WT1-specifik immunterapi
CY1107545T1 (el) Μεθοδοι για την προκληση θανατου καρκινικων κυτταρων και υποχωρησης του ογκου
CY1114050T1 (el) Μονοκλωνικα αντισωματα εναντι claudin-18 στην αγωγη εναντι καρκινου
DE60027564D1 (de) Tek-antagonisten
DE69734605D1 (de) Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
ATE500844T1 (de) Detektion der mcsp-oberflächenexpression einer zelle
CY1114340T1 (el) Συνθεσεις και χρησεις για θεραπεια σκληρυνσης κατα πλακας
AU9660801A (en) Compositions and methods for wt1 specific immunotherapy
AR021849A1 (es) Composiciones y metodos para la inmunoterapia especifica de wt1
AR031250A1 (es) Composiciones y metodos para la terapia y el diagnostico del cancer de pulmon
DE69942827D1 (de) Verwendung der epothilons zur behandlung der krebs
NO20064794L (no) Anvendelse av anti-alfa5beta1-antistoffer for inhibering av kreftcelleproliferasjon
HK1175846A1 (en) Cytotoxicity mediation of cells evidencing surface expression of cd44 cd44
DE60017141D1 (de) Replikationskompetente anti-tumor vektoren
SE7606971L (sv) Adriamycinestrar
DK0889969T3 (da) Rekombinante adenovirale til genterapi af humane tumorer
MX2021005400A (es) Terapia del cancer con celulas inmunitarias anti-ptk7.
ES2166900T3 (es) Derivados de ara-c.
WO2020176461A3 (en) Methods and compositions for treating neuroendocrine prostate cancer
ES2180985T3 (es) Derivados de taxano, su preparacion y formulaciones que los contienen.
AR023726A1 (es) Terapia con gch para el tratamiento del cancer de mama
ES2138574T3 (es) Composicion inmunogenica a base de particulas liberadas por el tumor.
MX2023006087A (es) Formulaciones liofilizadas de tegavivint.
AR023794A1 (es) Antigeno asociado con tumores